317OAssociation of survival and blood-based genomic signature with atezolizumab for patients with second-line and third-line EGFR wild-type non-small cell lung cancer: Pooled analysis of individual patient data from the POPLAR and OAK trials
Yu, Y, Li, A, Chen, Y, Li, Q, Ou, Q, Lin, D, Zhang, W, Li, Z, Hu, H, Yao, HVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz438
Date:
November, 2019
File:
PDF, 94 KB
2019